Before injecting hyaluronic acid (HA) filler into high-risk zones of the face, considerable caution must be exercised, including careful selection of the most appropriate filler, volume, and injection technique. Rare but severe adverse events have occurred during and after injection of HA filler in or around the periorbital region, such as skin necrosis and blindness. In the present case, involving a 57-year-old woman, approximately 0.1 mL of HA was injected into each side of the glabella to minimize wrinkles. The filler was injected into the dermis, utilizing the linear threading method. Proper care and caution were exercised before and during the procedure. Two days later, purple discoloration and erythema were observed in the left glabellar zone and forehead. A biopsy specimen was obtained and, based on histopathologic examination, frontal skin necrosis secondary to vascular occlusion was diagnosed. The likely cause and mechanism of the embolism will be discussed. To the author's knowledge, histopathologic findings of an intravascular remnant after injection of HA appear to be rare.
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Many patients seek biodegradable dermal fillers such as hyaluronic acid (HA) to correct the appearance of wrinkles and create a smooth contour. HA filler also has been utilized as an alternative to invasive rhinoplasty, which may involve prosthetic (silicone) implants or ear cartilage grafts. To augment the nose, it is easier and less invasive to inject HA filler into the dorsum or tip. However, there have been reports of severe complications, such as skin necrosis (in many areas) and blindness, following injection of HA filler near the eyes. Fortunately, the mechanisms behind such adverse events have been elucidated. [1] [2] [3] [4] In the present case, vascular occlusion occurred after injection of HA filler. Histopathologic investigation led to findings of skin necrosis, believed to result from injection of the filler. An intravascular remnant was observed, which appeared to be HA. Therefore, this rare case is presented to serve as a cautionary reminder to physicians of the serious events that can occur from injection of HA-based fillers.
CASE PRESENTATION
In October 2014, two days after her most recent injection of HA filler, a 57-year-old woman presented with symptoms of erythema, purple discoloration, and severe pain extending from the left glabella to the top of the forehead.
Previously the patient had received multiple injections of HA filler into the glabella, forehead, and nasolabial folds (from 2011 through 2014) to correct the appearance of wrinkles. Except for mild and transient purple discoloration, those procedures had been uneventful. Occasionally, at the patient's request, a small amount of the remaining HA filler was injected into her nasolabial folds and marionette lines. In addition, she had routinely undergone injection of onabotulinumtoxinA into the glabella and forehead, at 6-month intervals.
In October 2014, the patient received injection of HA filler (Teosyal First Lines; TEOXANE, Geneva, Switzerland) into her marionette lines (0.4 mL), glabellar region (0.2 mL [0.1 mL each side]), and above the left eyebrow (0.1 mL). The total dose was 0.7 mL. She had received this particular filler multiple times previously. The linear threading method was utilized in all locations of dermal injection. While carefully checking blood aspiration, the needle was slowly injected and withdrawn in a linear pattern. Nothing unusual was noted during the procedure or in the patient's response to it. Two days later, she returned to the clinic with purple discoloration, erythema, and pain in areas extending from the left eyebrow to the forehead. At presentation, purple discoloration and erythema were observed from the left glabella to the forehead. Erythema also was present in the hair-bearing parietal region of the scalp skin and was especially prominent around the hairline, where the skin was dark red ( Figure 1A ). The patient was afebrile and had no motor deficits in the forehead or eyebrow. I inquired as to what had happened in the 2 days since the injection; the patient replied that she had not been unduly concerned at first because she thought it was just internal bleeding. She also remarked that the injection had been more painful than usual, and that the pain had persisted after she returned home. I explained to the patient that the diagnosis was most likely skin necrosis. Hyaluronidase was not injected because the patient did not agree to it.
Key Testing
No blood test was performed. Five millimeters of dark red skin of the forehead, near the hairline, was obtained for biopsy following local injection of anesthesia (0.1 mL of 1% xylocaine with epinephrine). The sample was processed routinely for histopathologic evaluation ( Figure 1A) . Performance of the biopsy and histopathologic investigation complied with guidelines of the Declaration of Helsinki, and informed consent for both procedures was obtained from the patient.
Role of Hyaluronidase
Before injecting the filler, I had explained to the patient the risks of these injections, including embolism, and that hyaluronidase is needed to dissolve injected filler. However, I did not warn her that, once an embolism occurs, hyaluronidase may still be injected, nor had I explained the effects of hyaluronidase administration after an embolism occurs. Two days after injection of the filler, when she presented with the complications, I did explain that early administration of hyaluronidase can delay the progression of skin necrosis and improve the area, and that if administration of hyaluronidase is delayed or not done at all, there is risk of scarring and changes in pigmentation in the affected area. However, the patient did not agree to receive hyaluronidase.
Histologic Findings
Hematoxylin-eosin staining showed skin necrosis throughout the entire epidermis, down to the midreticular layer of the dermis ( Figure 2B ). Although inflammatory cell infiltration of the stroma was scarce, some inflammatory cells (eg, lymphocytes and neutrophils) were found in the perifollicular region. Below the midreticular dermis, weak basophilic amorphous matter was present in a blood vessel ( Figure 2C ). Elastica van Gieson staining showed lack of an internal elastic membrane and presence of a thin vessel wall; therefore, the residual matter was blocking a vein ( Figure 2D ). The residual matter tested negative by periodic-acid Schiff staining ( Figure 2E ) and positive by alcian blue staining ( Figure 2F ), indicating with high likelihood that the substance was HA.
Treatment
From 2 days post-injection, the affected area was treated every 12 hours with antibiotic ointment (10-g tube; 5 g per application). I applied the ointment the first time; the patient did the same before going to bed at night. She continued this treatment through 9 days post-injection ( Figure 1A-C) .
Ten days after injection, the skin tone began to improve and, at the patient's request, the scar was covered to keep it moist until 1 month post-injection ( Figure 1D -E). I strictly advised her to avoid exposure to sunlight and to apply a UVA/UVB sunscreen containing a sun protection factor of at least 30. Figure 1F shows the condition of her forehead skin 9 months after the injections; no scarring or changes in pigmentation were observed.
DISCUSSION
Reported complications after injection of HA filler range from mild events (eg, erythema and swelling) to severe effects such as skin necrosis and blindness. [1] [2] [3] [4] The physician must be extremely careful. Injection methods include serial puncture, linear threading, cross-hatching, fanning, and multiple-honeycomb. 5 I apply different methods for different regions. With respect to the size and type of needle, I utilize a 30-gauge short needle. Because the filler is a gel rather than a liquid, great pressure is required on the syringe plunger. When observing HA being injected through the tip of the needle at 250× magnification, it is understandable that substantial pressure would be required to release it (Figure 3) . Small-needle injection of HA filler at a volume or pressure that is too high can injure a vessel and cause ischemic necrosis.
In particular, Khan et al 6 concluded that the amount of filler applied to the glabellar region per treatment session should not exceed 0.085 mL, because the average volume of the supratrochlear artery from the glabella to the orbital apex is 0.085 mL according to test results. Coleman 7 stated that, to avoid complications, the amount of filler injected with each pass in a single treatment session should remain below 0.1 mL. There are reports of necrosis caused by vascular occlusion after filler injection, especially into the glabellar and nasal regions, so extreme caution is required. [1] [2] [3] In 2014, Nonomura et al 4 reported on a 20-year-old woman who had HA injection to augment the dorsal nasal area; she experienced occlusion in the ophthalmic artery, which led to permanent blindness in the right eye. showed a thin vessel wall and absence of an internal elastic membrane; therefore, the remnant was located in the vein. (E) Findings from PAS staining (original magnification ×200) were negative, and (F) findings from alcian blue staining (original magnification ×200) were positive. HE, hematoxylin-eosin; EVG, Elastica van Gieson; PAS, periodic-acid Schiff.
Injection of autologous fat also can cause ophthalmic disorders, including blindness, [8] [9] [10] [11] [12] [13] [14] and bilateral blindness occurred in a patient after injection of calcium hydroxylapatite at a high volume. 15 According to Carruthers et al, 8 in many cases, the blindness was irreversible. Some cases of partial visual recovery have been reported. Blindness is a possibility because the branches of arteries in certain facial regions are small, such as branches of the supratrochlear artery. Accidental injection into the supratrochlear artery, supraorbital artery, or dorsal nasal artery (terminal branch of the ophthalmic artery) causes reverse flow of filler released when high pressure is applied to the syringe plunger, resulting in occlusion in the origin of the ophthalmic artery. 9 Interestingly, many reports of blindness after filler injection are from Asia. 16 This may relate to the fact that many Asian patients desire a European-looking nose and choose filler as an easy method to augment nasal tissue. In addition, there are reports of retrograde flow of filler into the internal carotid artery; once the syringe pressure is released, the filler is carried by normal arterial pressure, potentially forming an embolism in the middle cerebral artery and causing a brain infarction. [9] [10] [11] [12] [13] [14] The volume of HA required to augment the nose is much greater than the amount needed to address wrinkles. Higher volumes increase the risk of complications. Extreme caution must be exercised regardless of the injection site, but this is especially crucial when augmenting the nose. Moreover, the physician must explain the risk of blindness to the patient upfront, before injection is performed.
The HA filler used in the present case (Teosyal First Lines) received European CE marking in 2004. In Japan, this produce has not been approved by the Ministry of Health, Labour and Welfare. Therefore, physicians in Japan must import it individually and obtain the Yakkan Shoumei Certificate for Import of Medicines and Medical Devices.
The patient described herein had undergone injection of HA many times previously, and had not experienced a problem after those treatments. Moreover, I had not considered the volume of filler being injected into the glabella (0.1 mL per side) to be unsafe. However, others have suggested that in order to avoid vascular occlusion in the supratrochlear artery and other severe complications, the volume of filler to the glabella overall should be less than 0.1 mL. 6, 7 Hence, the volume used in the present case could be deemed risky. Consequently, I have become more careful about determining the appropriate volume of filler for each injection site. Also, because I used the linear threading method with a 30-gauge needle, it is possible that the needle itself damaged the vessel during injection or withdrawal, forcing filler into the vessel (Figure 4 ). Clinical and histologic findings in the present case demonstrated that the skin necrosis was caused by occlusion of the supratrochlear vein, resulting from the volume of filler and the injection technique ( Figure 4 ). The trust between physician and patient was solid, and the patient continued treatment at the clinic. Fortunately, the ischemic tissue healed without scarring or changes in pigmentation. It is imperative to establish a treatment protocol for managing such cases of vascular occlusion. If hyaluronidase is administered early, it can delay the progression of skin necrosis and improve the affected area. However, if the patient refuses it (as in the present case), there must be other options for management.
If HA is suspected to be in the vessel, administering hyaluronidase may result in an allergic reaction, and intravascular administration of hyaluronidase is a difficult technique. However, preclinical research by Chiang et al 17 suggests that administering both hyaluronidase and urokinase intravenously lowers the risk of flap necrosis. In their investigation, HA was injected into the artery of a skin flap to cause an embolism, after which hyaluronidase, urokinase, or both agents were administered intravenously. Although more studies are needed, this approach could be developed into an effective method to treat vascular occlusion resulting from HA injection and, in turn, prevent adverse events such as skin necrosis and blindness.
Although hyaluronidase was not utilized in the present case, the affected area healed without scarring or changes in pigmentation. However, the explanation of hyaluronidase to the patient beforehand was insufficient, which may have contributed to her lack of consent to receive it, which in turn delayed healing. Currently, I show the photograph of this patient's forehead to other patients, and I explain the mechanisms of skin necrosis owing to vascular occlusion. I emphasize that it is extremely important to return to the clinic as quickly as possible if skin changes are detected or if pain persists, and that it may be necessary to administer hyaluronidase.
I have always exercised extreme caution when injecting HA but, despite this, venous occlusion occurred in this case and led to skin necrosis. Since the incident, I have been utilizing the serial puncture method for high-risk zones of the face to ensure shallow injection of the dermis. In addition, the maximum total volume of filler has not exceeded 0.1 mL. I am also considering using a cannula for added safety.
Inoue et al 18 described a case of arterial embolization and skin necrosis of the nasal ala occurring after injection of dermal filler. The histopathologic findings in their case will serve as valuable information for future study. With numerous physicians and institutions currently utilizing HA fillers, it is likely that similar complications have occurred that may not have been reported. It is hoped that this report will further increase awareness of the serious risks associated with injecting HA and other dermal fillers.
CONCLUSIONS
Currently, minimization of wrinkles and augmentation of the nose can be accomplished easily by injection of HA. However, severe complications can occur, such as skin necrosis and blindness, even in patients who have undergone many such injections without adverse effects. Therefore, extreme caution should be exercised before and during these procedures.
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